Class: Antibiotic, Cephalosporin
- Capsules 500 mg (as monohydrate)
- Tablets 1 g (as monohydrate)
- Powder for Oral Suspension 250 mg/5 mL
- Powder for Oral Suspension 500 mg/5 mL
Inhibits mucopeptide synthesis in bacterial cell wall.
Rapidly absorbed. C max is about 16 mcg/mL (500 mg dose) and 28 mcg/mL (1,000 mg dose).
20% protein bound.
More than 90% is excreted in the urine as unchanged drug within 24 h; t ½ is 78 to 96 min.
Special PopulationsRenal Function Impairment
The t ½ is increased. Adjust dose.
Indications and Usage
Treatment of infections of urinary tract, skin and skin structures; treatment of pharyngitis and tonsillitis caused by susceptible strains of specific microorganisms.
Hypersensitivity to cephalosporins.
Dosage and AdministrationAdults
PO 1 to 2 g/day in single dose or 2 divided doses.Children
PO 30 mg/kg/day in single dose or 2 divided doses.
- Administer with food or milk if GI upset occurs.
Oral suspension must be refrigerated and will remain stable for up to 14 days. Do not freeze. Shake well before use.
Inhibition of renal excretion of cefadroxil.
Laboratory Test Interactions
May cause false-positive urine glucose test results with Benedict solution, Fehling solution, or Clinitest tablets but not with enzyme-based tests (eg, Clinistix , Tes-tape ); false-positive test results for proteinuria with acid and denaturization-precipitation tests; false-positive direct Coombs test results in certain patients (eg, those with azotemia); false elevations in urinary 17-ketosteroid values.
Nausea; vomiting; diarrhea; anorexia; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis.
Pyuria; renal dysfunction; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy.
Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; decreased platelet function; anemia; aplastic anemia; hemorrhage.
Hepatic dysfunction, abnormal LFT results.
Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme and toxic epidermal necrolysis; serum sickness–like reactions (eg, skin rash, polyarthritis, arthralgia, fever); candidal overgrowth.
MonitorResponse to therapy
Monitor patient's response to therapy. Notify health care provider if infection does not improve or appears to worsen.Side effects
Monitor patient for GI, DERM, and general body side effects, and signs of superinfection. Inform health care provider if noted and significant. Immediately report severe diarrhea, diarrhea containing blood or pus, or severe abdominal cramping.
Category B .
Excreted in breast milk.
In infants, consider benefits relative to risks. Drug may accumulate in newborns.
Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients because of possible cross-reactivity.
Use drug with caution in patients with renal function impairment. Dosage adjustment based on renal function may be required.
May result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Consider in patients in whom diarrhea develops.
- Instruct patient to complete full course of therapy.
- Instruct patient to check body temperature daily. If fever persists more than a few days or if high fever (above 102°F) or shaking chills are noted, notify health care provider immediately.
- Advise patient to maintain normal fluid intake while using this medication.
- Advise diabetic patient to use enzyme-based tests (eg, Clinistix , Testape ) for monitoring urine glucose because drug may give false results with other tests.
- Instruct patient to report these symptoms to health care provider: nausea, vomiting, diarrhea, skin rash, hives, muscle or joint pain.
- Instruct patient to report signs of superinfection: black “furry” tongue, white patches in mouth, foul-smelling stools, vaginal itching or discharge.
- Warn patient that diarrhea that contains blood or pus may be a sign of serious disorders. Tell patient to seek medical care and not to treat at home. Instruct patient to seek emergency care immediately if wheezing or difficulty in breathing occurs.
Copyright © 2009 Wolters Kluwer Health.